Principal forecaster for in-line North American brands with combined sales of over $1 billion, covering therapeutic areas of oncology, neurology & endocrinology/rheumatology, and including short- and long-term planning for two orphan (rare disease) drug assets within these arenas. - Lead forecasting team in execution of forecast model development and delivery. - Manage presentation of forecast updates to brand & executive leadership (global + North American). - KPI development and delivery of weekly and monthly forecast performance-tracking reports. - Collaborated with commercial & finance leads, executive management, and internal analytics & market research teams, to design and launch a budget forecasting process covering all in-line brands

Led revenue and volume-demand planning processes for both in-line products and pipeline assets. - Delivered tactical and strategic, indication-level forecasts, and set as well as monitored key performance indicators, for a hematology-oncology product generating over $125 million in annual sales. - Collaborated with functional leaders (commercial, clinical, project management, finance, and supply chain), to build forecast models and then execute strategic forecasts for clinical assets in the company’s pipeline portfolio covering indications in endometrial cancer, MDS and AML. - Led presentation of forecast updates to commercial and executive leadership, and collaborated with finance to assemble presentations of product growth plans for board members and investors

Forecasting and strategic analyses informing global development and commercialization decisions related to GSK’s portfolio of mid- and late-stage hematology-oncology assets. - Global forecast lead for US and EU product launches of a first-in-class multiple myeloma therapy, including collaboration with global market research lead in the deployment of a conjoint analysis piece of primary market research informing key inputs into a multi-scenario product forecast. - Collaborated with global and local market research & insights teams to project current-label and label-expansion uptake, as well as to derive insights informing global life-cycle management strategies. - Led collaborative forecasting-competitive intelligence project producing a tool informing future market share estimates for forecasts of early- and mid-stage projects in select hematological malignancies.

Served in various roles as commercial assessment principal for external BD&L targets, as forecasting lead for select internal development-stage assets, and as primary forecaster for select U.S. in-line franchises.- Commercial assessment lead (market research, analytics & forecasting) supporting global in-licensing and acquisition opportunities. Led vendor selection process and deployed qualitative and quantitative primary market research methodologies to inform a forecast’s patient-to-product flows, and to assess physician, patient & payer variables impacting the forecast.- Built strategic forecasts and conducted scenario and sensitivity analysis for five product candidates in Teva’s clinical-stage neuropsychology and pain portfolio. - In-line forecasting for the >$500 million U.S. Teva Women’s Health franchise (10 products; >50 SKUs), including market evolution & share projections as well as unit-demand and net sales forecasting.- Lead provider of competitive analytics and insights in support of U.S. generics business, including analysis and visualization of market data (IMS and similar) as well as GX-pipeline data (FDA and IPD databases).

Managed forecasting team and led market assessment and forecast build processes, delivering decision-informing forecasts to commercial executive management, commercial and finance team leaders, senior R&D personnel and BD&L senior management. - Strategic forecasts and project cash flow and valuation-sensitivity analyses for pipeline and BD&L-targeted assets with over $2 billion in projected peak sales and expected NPVs totaling over $500 million. - Tactical revenue and volume forecasts for in-line global assets with over $200 million in sales. - Led market assessment, forecasting, financial valuation and deal structure analysis for three late-stage clinical development acquisition/in-licensing targets. Analyses guided due diligence, informed negotiation, and directed management decisions on high-risk transactions prospectively valued at over $500 million. - Led product forecasting efforts and production-cost, investment and ROI analyses informing global development, commercial launch plans, and manufacturing in/out-sourcing tactics for a $60 million global expansion of assets facing near-term North American generic entry and sales declines. - Led quantitative portfolio optimization project, using a multi-dimensional, efficient frontier approach to evaluate risk, value and return trade-offs, pursuant of selecting optimal 3-5 year R&D investment plan. - Refined and standardized a data-driven approach for setting market access vs. price parameters useable in forecasting the revenue potential of novel, early-stage development assets in cash-pay dominated countries.

Strategic planning, forecasting, market & business analytics, financial modeling & valuation services, and market & technology assessment supporting franchise development, product portfolio planning, and business development & licensing decisions. Select assignments include: - Managed evaluation of a pharmaceutical company’s proposed acquisition of an infectious disease diagnostic product line generating $180 million in revenues. Assembled a 10-year global pro forma P/(L), led a cross-functional team in preliminary due diligence and delivery of supporting technology and market assessments, and constructed a valuation model used to support strategic and tactical transaction rationales. - Portfolio trade-off, risk-adjusted NPV and ROI, and situation analyses involving global unit-sales, revenue, and variable resource allocation projections for the proposed product behind a biopharmaceutical company’s $50 million investment to expand and diversify its portfolio in transfusion medicine. - Revised a medical technology company’s long-term financial plan, and guided prioritization of R&D projects as well as formulation of international partnering strategies for select product candidates. Refined product sales and R&D cost forecasts and built a fully-integrated long-term, corporate financial model. - Sales forecasting, business analytics and performance reporting, sales force alignment, and incentive compensation plan design and implementation for a newly-launched CLIA lab diagnostics product.

Developed and executed product partnering, licensing, and acquisition strategies for life sciences clientele. Notable assignments include: - Led partnering effort for a disposable, acute care medical product in early-stage development. Directed engagement of and led presentations to prospective corporate partners and investors. Developed presentation materials on underlying technology and target product market, and constructed a detailed financial model linking various product investment options to distinct future product sales forecast and valuation scenarios. - Developed global out-licensing strategy for a diagnostic imaging technology in late-stage development. Identified business partners for global distribution and defined partnering structures capable of satisfying the company’s current cash needs and reducing its share of current development risk, while still allowing it to significantly share in future revenue streams. - Cash flow modeling and NPV analysis guiding the re-structuring of a co-development / co-promotion partnership for an oncology product candidate into a $100 million milestones & royalties out-licensing arrangement. - Saved a diversified medical products company $175 million in its proposed acquisition of a patient monitoring technology. Directed management’s adjustment of valuation models by elucidating key market dynamic and reimbursement issues, as well as by identifying limits of the existing clinical development plan to generate data capable of driving physician and payer acceptance and uptake - Expanded and prioritized a detailed list of medical technology acquisition targets for a leading orthopedics manufacturer seeking to add over $50 million in product revenues to its intra-operative care business.

Lead internal provider of forecasting, financial modeling and analysis, valuation, market analytics and competitive intelligence driving new product planning and business development & licensing effort. - Sales forecasting, financial modeling, valuation, and transaction structure analysis enabling the $14 million acquisition of patent and trademark rights related to a $100 million cardiovascular product line. - Market, technology and financial assessments of prospective product and corporate acquisition targets aligning with 5-year strategic plan for aggressive expansion of a $150 million acute and cardiovascular care franchise. - Constructed and maintained 10-year, fully-integrated corporate financial model used by executive management and functional leaders to guide development and analysis of key assumptions underlying corporate and product portfolio strategic plans. Output included project-specific income and cash flow statements for commercial and development-stage portions of the cardiovascular and oncology product portfolios, as well as valuation, financial ratio, and portfolio risk vs. value metrics facilitating quantitative assessment of the corporate strategic plan. - Guided commercial investment and manufacturing resource allocation plans for an acute care cardiovascular product generating over $40 million in annual sales. Led financial modeling and valuation efforts, including detailed 15-year projections of product revenue, sales & marketing costs, fixed and variable manufacturing costs, and critical capital and IP expenditures. - Transaction structure, valuation, and pro forma financial impact analyses guiding initial negotiations and preliminary term sheet submission for a prospective co-development and global commercialization arrangement involving cross-promotion of an internal product candidate and a partner’s product candidate, both in late stage development for different gastrointestinal conditions.

Led financial modeling and analysis, valuation, and product forecasting efforts for strategic planning, business development & licensing, and product marketing teams.• Key Achievements: - Led internal financial and valuation analysis driving negotiation and closing of $719 million corporate sale to Genzyme. - Strategic business assessment, including product forecasting, pro forma financial model development and transaction structure analyses, guiding the formation of $31 million joint commercialization partnership for a newly-approved oral renal care therapeutic. - Financial modeling, analyses and investor presentation preparation for a $110 million follow-on stock offering. - Led revenue and cost forecasting, risk-adjusted cash flow and NPV analyses, and transaction structure analyses for a proposed $100 million licensing, development and commercialization agreement involving a product candidate in mid-stage clinical development for catheter-based infections in the dialysis setting.- Construction and monthly update of sales forecast and corporate financial plan for a 3-product, $125 million renal care franchise, including income statement, cash flow, and balance sheet projections.

Provided financial modeling, analysis, and valuation facilitating the execution of over $1.4 billion in equity & debt financings, corporate mergers & acquisitions, joint venture arrangements and licensing transactions.